Featured Publications
Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal
Jackson A, Papke RL, Damaj MI. Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal. Psychopharmacology 2018, 235: 1897-1905. PMID: 29549391, PMCID: PMC6015775, DOI: 10.1007/s00213-018-4879-7.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsΑ7 nicotinic acetylcholine receptorMecamylamine-precipitated nicotine withdrawalNicotine withdrawal behaviorsNicotine withdrawalNicotinic acetylcholine receptorsSomatic signsPharmacological modulationNon-selective nAChR antagonist mecamylamineAcetylcholine receptorsNicotine withdrawal-induced hyperalgesiaWithdrawal-induced hyperalgesiaDose-related fashionNicotine withdrawal signsNAChR antagonist mecamylamineAnxiety-like behaviorAntagonist mecamylamineWithdrawal signsPreclinical dataNicotine rewardΑ7 nAChRsAgonist PNU282987Mouse modelWithdrawal behaviorAllosteric modulators
2021
Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms
Hamouda AK, Bautista MR, Akinola LS, Alkhlaif Y, Jackson A, Carper M, Toma WB, Garai S, Chen YC, Thakur GA, Fowler CD, Damaj MI. Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms. Neuropharmacology 2021, 190: 108568. PMID: 33878302, PMCID: PMC8169606, DOI: 10.1016/j.neuropharm.2021.108568.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsWithdrawal symptomsHypothermic effectMale miceAntinociceptive effectΑ4β2 nAChRsNicotine withdrawal-induced hyperalgesiaNAChR isoformsNicotine's antinociceptive effectsWithdrawal-induced hyperalgesiaNicotine withdrawal symptomsNicotine addiction treatmentAnxiety-like behaviorNicotinic acetylcholine receptorsDose-dependent mannerNociceptive responsesNicotine withdrawalNicotine intakeSomatic signsNicotine abstinencePharmacological effectsNicotine useAcetylcholine receptorsAffective symptomsPathophysiological processes
2018
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 2018, 138: 72-79. PMID: 29860196, PMCID: PMC6054891, DOI: 10.1016/j.neuropharm.2018.05.025.Peer-Reviewed Original ResearchConceptsEffects of vareniclineNicotine withdrawal signsNicotine rewardΑ5 nAChRWithdrawal signsHigh doseKnockout miceΒ2-nAChRsNicotine withdrawal-induced hyperalgesiaAdministration of vareniclineWithdrawal-induced hyperalgesiaΑ7 knockout miceDose-related mannerNicotinic acetylcholine receptorsΑ5 knockout micePlace preference testVarenicline doseCessation treatmentNicotine withdrawalSomatic signsVareniclineΑ7 nAChRsMouse modelCPP testNicotinic subtypes
2017
Assessment of nicotine withdrawal-induced changes in sucrose preference in mice
Alkhlaif Y, Bagdas D, Jackson A, Park AJ, Damaj IM. Assessment of nicotine withdrawal-induced changes in sucrose preference in mice. Pharmacology Biochemistry And Behavior 2017, 161: 47-52. PMID: 28919072, PMCID: PMC6408212, DOI: 10.1016/j.pbb.2017.08.013.Peer-Reviewed Original ResearchConceptsSucrose preference testNicotine withdrawalSpontaneous nicotine withdrawalLight-dark box testDark box testPositive affective stimuliSucrose preferenceAffective signsSmoking relapse ratesΑ6 KO miceSubcutaneous osmotic minipumpsWithdrawal-induced changesUnderlying neurobiological factorsPreference testRelapse rateOsmotic minipumpsKO miceTobacco useNicotine dependenceKnockout miceAnimal modelsNicotinic subunitsDay 15MiceDifferent dosesReversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice
Hamouda AK, Jackson A, Bagdas D, Damaj M. Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice. Nicotine & Tobacco Research 2017, 20: 903-907. PMID: 29059422, PMCID: PMC5991208, DOI: 10.1093/ntr/ntx183.Peer-Reviewed Original ResearchConceptsNicotine withdrawal symptomsSpontaneous nicotine withdrawalNicotine withdrawal signsNicotine withdrawalWithdrawal symptomsPositive allosteric modulatorsCessation aidWithdrawal signsMale miceMouse modelAllosteric modulatorsNicotinic acetylcholine receptor agonistNAChR-positive allosteric modulatorsAcetylcholine receptor agonistDose-dependent reversalICR male miceΑ4β2 nicotinic acetylcholine receptorsPositive allosteric modulationAnxiety-like behaviorNicotinic acetylcholine receptorsPotential clinical useAcute injectionRelapse rateTobacco smokingDay infusion
2015
Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice
Jackson KJ, Jackson A, Carroll FI, Damaj MI. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 2015, 97: 270-274. PMID: 26044637, PMCID: PMC4537361, DOI: 10.1016/j.neuropharm.2015.05.023.Peer-Reviewed Original ResearchConceptsNicotine withdrawal syndromeWithdrawal syndromeKOR antagonistsAnxiety-related behaviorNicotine withdrawalSomatic signsKappa Opioid Receptor SignalingSelective KOR antagonistAffective nicotine withdrawal signsNicotine withdrawal signsOpioid receptor signalingUseful therapeutic agentShort actingHotplate latencyWithdrawal signsPharmacodynamic profileClinical studiesMood disordersLY2456302Animal modelsPlace aversionDrug dependenceTherapeutic potentialDecreased expressionAntagonist